Results 31 to 40 of about 15,824 (192)

The Revival of Aztreonam in Combination with Avibactam against Metallo-β-Lactamase-Producing Gram-Negatives: A Systematic Review of In Vitro Studies and Clinical Cases

Antibiotics, 2021
Infections caused by metallo-β-lactamase (MBL)-producing Enterobacterales and Pseudomonas are increasingly reported worldwide and are usually associated with high mortality rates (>30%).
Carola Mauri, Alberto Enrico Maraolo, Stefano Di Bella, Francesco Luzzaro, Luigi Principe   +4 more
doaj   +1 more source

AmpC β-lactamase induction by avibactam and relebactam [PDF]

, 2017
Background: Diazabicyclooctanes, e.g. avibactam and relebactam, are a new class of β-lactamase inhibitors. Their spectrum includes AmpC enzymes, but it is important to understand whether they also induce these enzymes.
Jamrozy, Dorota, Livermore, David M, Mushtaq, Shazad, Nichols, Wright W, Woodford, Neil, Young, Katherine   +5 more
core   +1 more source

Antimicrobial Activities of Aztreonam-Avibactam and Comparator Agents against Enterobacterales Analyzed by ICU and Non-ICU Wards, Infection Sources, and Geographic Regions: ATLAS Program 2016–2020

Antibiotics, 2023
Increasing antimicrobial resistance among multidrug-resistant (MDR), extended-spectrum β-lactamase (ESBL)- and carbapenemase-producing Enterobacterales (CPE), in particular metallo-β-lactamase (MBL)-positive strains, has led to limited treatment options ...
Denis Piérard, Elizabeth D. Hermsen, Michal Kantecki, Francis F. Arhin   +3 more
doaj   +1 more source

Correction to "Persistent <i>Burkholderia cepacia</i> Bacteremia in Reconstructive Surgery: Resistance to Ceftazidime/Avibactam and Co-Trimoxazole With Risk of Infective Endocarditis-A Case Report". [PDF]

Clin Case Rep
Clinical Case Reports, Volume 14, Issue 2, February 2026.
europepmc   +2 more sources

Cephem Potentiation by Inactivation of Nonessential Genes Involved in Cell Wall Biogenesis of ß-Lactamase-Producing Escherichia coli [PDF]

, 2017
Reversal of antimicrobial resistance is an appealing and largely unexplored strategy in drug discovery. The objective of this study was to identify potential targets for “helper” drugs reversing cephem resistance in Escherichia coli strains producing β ...
Baker, K R, Guardabassi, L, Jana, B, Sigurðardóttir, H H   +3 more
core   +2 more sources

In Vitro Activity Comparison of Ceftazidime–Avibactam and Aztreonam–Avibactam Against Bloodstream Infections With Carbapenem-Resistant Organisms in China

Frontiers in Cellular and Infection Microbiology, 2021
ObjectivesThe aim of this work was to investigate the activity of ceftazidime–avibactam (CZA) and aztreonam–avibactam (AZA) against bloodstream infections caused by carbapenem-resistant organisms (CROs).MethodsNon-duplicate CROs, including 56 carbapenem ...
Wei Yu, Luying Xiong, Qixia Luo, Yunbo Chen, Jinru Ji, Chaoqun Ying, Zhiying Liu, Yonghong Xiao   +7 more
doaj   +1 more source

The 2018 Garrod Lecture: Preparing for the Black Swans of Resistance [PDF]

, 2018
The need for governments to encourage antibiotic development is widely agreed, with ‘Market Entry Rewards’ being suggested. Unless these are to be spread widely – which is unlikely given the $1 billion sums proposed– we should be wary, for this approach ...
Livermore, David
core   +1 more source

Cyclic Boronates Inhibit All Classes of β-Lactamase [PDF]

, 2017
β-Lactamase-mediated resistance is a growing threat to the continued use of β-lactam antibiotics. The use of the β-lactam-based serine-β-lactamase (SBL) inhibitors clavulanic acid, sulbactam, tazobactam, and, more recently, the non-β-lactam inhibitor ...
Brem, J, Cahill, ST, Cain, R, Fishwick, CWG, Lohans, CT, McDonough, MA, Mohammed, J, Oswin, HP, Schofield, CJ, Spencer, J, Wang, DY, Wareham, DW   +11 more
core   +5 more sources

Antimicrobials: a global alliance for optimizing their rational use in intra-abdominal infections (AGORA) [PDF]

, 2016
Intra-abdominal infections (IAI) are an important cause of morbidity and are frequently associated with poor prognosis, particularly in high-risk patients.
A, A, A, A, A, A, A, A, A, A, A, A, A, AA, AC, AH, AJ, AK, AK, AM, AW, B, B, B, B, BJ, C, C, C, C, CA, CA, CE, D, D, D, DG, DP, E, EA, EE, F, F, F, F, FA, FM, FM, G, G, G, G, G, G, G, GA, GP, H, H, H, H, HAS, HE, I, I, I, I, IJ, J, J, JA, JE, JF, JG, JJ, JJ, JL, JR, JR, JR, JV, K, K, K, K, KA, KC, KYY, L, LJ, M, M, M, M, M, M, M, M, M, M, M, M, M, MA, MA, MA, MA, MC, MG, MM, MN, MP, N, N, NT, O, OR, P, P, P, P, PF, PK, R, R, R, R, R, R, R, RB, RG, RM, RR, RR, RS, RV, S, S, S, S, S, S, S, S, S, Sartelli, SJ, SK, SK, SM, SR, SR, SY, T, T, TL, TM, V, V, VG, VN, W, W, W, WL, WR, Y, YF, YH, YR, YS, Z, ZJ   +173 more
core   +4 more sources

WCK 4234, a novel diazabicyclooctane potentiating carbapenems against Enterobacteriaceae, Pseudomonas and Acinetobacter with class A, C and D β-lactamases [PDF]

, 2017
Background: Several diazabicyclooctanes (DBOs) are under development as inhibitors of Class A and C -lactamases. Inhibition of OXA (Class D) carbapenemases is variable, with those of Acinetobacter spp. remaining notably resistant. We describe a novel DBO,
Anna Vickers, Clinical and Laboratory Standards Institute, David M. Livermore, Neil Woodford, Shazad Mushtaq   +4 more
core   +1 more source